Sensei biotherapeutics presents preclinical data for sns-101, a conditionally active vista-blocking antibody, at the sixth annual cri-enci-aacr international cancer immunotherapy conference: translating science into survival

- sns-101 demonstrated a favorable pharmacokinetic profile, enhanced anti-tumor effects in combination with anti-pd-1 antibodies and a significantly improved cytokine release profile as compared to a ph-independent vista antibody
SNSE Ratings Summary
SNSE Quant Ranking